ARNA could start to become quite interesting play on the run up to the NDA, The FDA has notified the company of the tentative scheduling of an Endocrinologic and Metabolic Drugs Advisory Committee meeting on September 16, 2010, for the review of the lorcaserin New Drug Application. The shares are trading up pre market on a small volume of 43,000 trading up $0.18 cents from close last night of $3.05. With a trading range of $2.70 low to a high of $5.93 in September. We could see a nice substantial run up to the FDA date, ARNA is trading of its recent lows, If I was a buyer I would be waiting for a possible retraction in price. Arena Pharmaceuticals, Inc. ARNA

Kommentare sind geschlossen.